Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

March 13, 2020March 13, 2020

Platinum Chemo No Better than Standard in BRCA-mutated Early BC, Trial Finds

News

Women with newly diagnosed breast cancer who carry a mutation in their BRCA genes may continue to receive the standard pre-surgery chemotherapy regimen used for other breast cancer patients, according ... Read more

February 24, 2020March 5, 2020

Magseed Approval Extended in Europe for Soft Tissues, Long-Term Implantation

News

Magseed, a small magnetic marker by Endomag designed to accurately mark the site of cancer cells before surgery, is now approved in Europe for use in any soft tissue and ... Read more

January 20, 2020January 20, 2020

Leronlimab Combo Shows Promise for Metastatic TNBC in Early Phase 1b/2 Trial Data

News

Investigational therapy leronlimab is showing promise as a potential therapy for people with CCR5-positive metastatic triple-negative breast cancer (mTNBC), early data from a Phase 1b/2 clinical trial suggest. The open-label ... Read more

January 10, 2020January 10, 2020

Keytruda, Imprime PGG Combo Increases Overall Survival in Metastatic Triple-negative BC, Data Show

News

Treatment with Biothera Pharmaceutical‘s Imprime PGG appears to increase the sensitivity of chemotherapy-resistant metastatic triple-negative breast cancers (mTNBC) to the immune checkpoint inhibitor Keytruda (pembrolizumab), interim data from a Phase 2 study ... Read more

December 17, 2019January 15, 2020

Dosing Complete in Phase 2 Trial Evaluating Lymfactin for BC Treatment-Associated Lymphedema

News

Herantis Pharma has completed patient dosing in its Phase 2 trial evaluating the investigational gene therapy Lymfactin for secondary lymphedema — a common complication of breast cancer treatment caused by ... Read more

November 11, 2019November 11, 2019

Blood Test May Identify Breast Cancer Years Before Symptoms Appear, Pilot Study Suggests

News

A simple blood test – which measures antibodies against certain tumor proteins, or antigens — may identify breast cancer up to five years before clinical signs of cancer are evident, ... Read more

September 16, 2019

TNBC Patient Given Investigative Antibody, Leronlimab, Under Emergency Exception

News

A metastatic triple-negative breast cancer (TNBC) patient is being treated with CytoDyn’s investigational leronlimab (PRO 140) under an emergency investigational new drug (IND) application granted by the U.S. Food and ... Read more

September 13, 2019September 13, 2019

FDA to Review Nerlynx Combo as Third-line Treatment for HER2-positive Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has agreed to review Puma Biotechnology’s application seeking approval of Nerlynx (neratinib), in combination with capecitabine, to treat HER2-positive breast cancer patients with metastatic disease, the ... Read more

September 9, 2019September 9, 2019

Nerlynx Granted FDA’s Orphan Drug Status for Treating Breast Cancer with Brain Metastases

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Puma Biotechnology’s Nerlynx (neratinib) for the treatment of HER2-positive breast cancer in women with brain metastases. Between 10 to 15% of ... Read more

August 19, 2019

Phase 2 Trial of NeuVax Vaccine for HER2-positive DCIS Fully Enrolled, Sellas Announces

News

The Phase 2 trial evaluating Sellas Life Sciences‘ cancer vaccine NeuVax as a treatment for women with early stage HER2-positive ductal carcinoma in situ (DCIS), a non-invasive breast cancer, has completed ... Read more